- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00212602
ONO-7436 Phase II Study in Japan
June 12, 2012 updated by: Ono Pharmaceutical Co. Ltd
ONO-7436 Phase II Study - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of ONO-7436 for the Prevention of Cancer Chemotherapy-Induced Nausea and Vomiting in Japan
The purpose of this study is to examine the efficacy and safety of ONO-7436 for the prevention of cancer chemotherapy-induced nausea and vomiting in patients with malignant tumor
Study Overview
Study Type
Interventional
Enrollment
420
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chubu, Japan
- Chubu Region Facility
-
Chugoku, Japan
- Chugoku Region Facility
-
Hokkaido, Japan
- Hokkaido Region Facility
-
Hokuriku, Japan
- Hokuriku Region Facility
-
Kanto, Japan
- Kanto Region Facility
-
Kinki, Japan
- Kinki Region Facility
-
Kyushu, Japan
- Kyushu Region Facility
-
Shikoku, Japan
- Shikoku Region Facility
-
Tohoku, Japan
- Tohoku Region Facility
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients age 20 years or older
- Patients with malignant tumor who are to be intravenously administered cisplatin as a single dose of 70 mg/m2 or more in under 3 hours
- Patients whose performance status is 0 to 2
- Other inclusion criteria as specified in the study protocol
Exclusion Criteria:
- In case of patients who are previously treated with cisplatin, those having no past history of vomiting as of administration of cisplatin
- Patients who had vomiting or dry vomiting within 24 hours before the initial administration of the moderate or severe emetic chemotherapy (including cisplatin) on Day 1 of the study
- Pregnant women, nursing women, women of child-bearing potential, women who wish to become pregnant or women using oral contraception
- Other exclusion criteria as specified in the study protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Patient proportion of complete response (no vomiting and no rescue treatment).
|
Secondary Outcome Measures
Outcome Measure |
---|
Proportion of patients with no vomiting, no rescue treatment, and no nausea (in each category or combination), frequency of vomiting, and time to first vomiting, and first rescue treatment.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Project Leader, Development Planning, Ono Pharmaceutical Co. Ltd
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2005
Study Registration Dates
First Submitted
September 13, 2005
First Submitted That Met QC Criteria
September 20, 2005
First Posted (Estimate)
September 21, 2005
Study Record Updates
Last Update Posted (Estimate)
June 14, 2012
Last Update Submitted That Met QC Criteria
June 12, 2012
Last Verified
June 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ONO-7436-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Tumor
-
Elpiscience Biopharma, Ltd.Shanghai Junshi Bioscience Co., Ltd.RecruitingNeoplasms | Solid Tumor | Malignant TumorChina
-
Daiichi Sankyo Co., Ltd.RecruitingAdvanced Solid Tumor | Malignant Solid TumorUnited States, Japan
-
Peking Union Medical College HospitalRecruiting
-
Capital Medical UniversityCompleted
-
Capital Medical UniversityCompleted
-
Asclepius Technology Company Group (Suzhou) Co....UnknownMalignant TumorChina
-
Seoul National University HospitalUnknown
-
University Hospitals Cleveland Medical CenterApollo Endosurgery, Inc.CompletedColon Malignant Tumor | Colon Benign TumorUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Bristol-Myers SquibbCompletedMalignant Solid TumorUnited States, France, Italy, Australia, Canada, Germany, Netherlands
Clinical Trials on ONO-7436
-
Ono Pharmaceutical Co. LtdCompletedVenous ThromboembolismUnited Kingdom
-
Ono Pharmaceutical Co. LtdCompleted
-
Ono Pharmaceutical Co. LtdCompleted
-
Ono Pharmaceutical Co. LtdTerminatedPain | Osteoarthritis, KneePoland, Hungary, Spain, Denmark, United Kingdom
-
Ono Pharma USA IncCompletedIrritable Bowel Syndrome (IBS)United States
-
Ono Pharma USA IncCompletedMajor Depressive DisorderUnited States
-
Ono Pharma USA IncCompleted
-
Ono Pharma USA IncTerminatedChemotherapy-Induced ThrombocytopeniaUnited States, Korea, Republic of, Russian Federation
-
Ono Pharmaceutical Co. LtdCompletedHealthy Post Menopausal WomenUnited Kingdom